On July 22, 2022, Shenzhen Eureka Biotechnology Co., Ltd. (hereinafter referred to as “EurekaBio”) and Shenzhen Bindebio Technology Co Ltd. (hereinafter referred to as “BinDeBio”) officially announced a strategic partnership. The collaboration was established through a signing ceremony attended by Mr. Ma Mo, CEO of EurekaBio, and Dr. Wan Xiaochun, Chairman of BinDeBio, who signed the agreement on behalf of their respective organizations.
The cell and gene industry is currently on the cusp of an industrial explosion, with China's development in the global field of cell and gene therapy rivaling that of the United States. Capitalizing on the global momentum in the cell and gene therapy industry, Shenzhen has created a highly conducive environment with favorable policies, legislative support, and talent attraction. The city's immense potential positions it as a strategic emerging sector capable of nurturing the growth of the cell and gene industry
As local enterprises deeply rooted in Shenzhen, EurekaBio, and BinDeBio are forging a strong collaboration through this strategic partnership. Their joint efforts will encompass regular visits and exchanges, process optimization for relevant products, collaborative research initiatives, and joint project applications. By working together on technological research and application, they aspire to deliver cutting-edge, reliable, and cost-effective novel therapies to patients. Together, they are actively driving the rapid development of the cell therapy industry within the Greater Bay Area.
Dr. Wan Xiaochun, Chairman of BinDeBio, remarked, “The Chinese cell and gene therapy industry is experiencing rapid expansion, with the emergence of numerous commendable biotechnology firms and a relatively comprehensive domestic industry chain. Our heavy reliance on imports for key upstream raw materials and equipment underscores the urgent need for achieving self-reliance and original innovation. EurekaBio's steadfast commitment to this field positions them to make significant breakthroughs. Its dedication not only expands the choices available to downstream enterprises but also enhances production efficiency and mitigates production risk. BinDeBio remains committed to pioneering innovative immunotherapy technologies, and we are delighted to establish this strategic collaboration with EurekaBio. We eagerly anticipate future synergistic partnerships in various domains, collectively empowering China's CGT industry.”
Mr. Ma Mo, CEO of EurekaBio, expressed his utmost satisfaction in establishing a strategic collaboration with BinDeBio. BinDeBio has established itself as a leader in CAR-T and TCR-T immunotherapy, demonstrating formidable capabilities in innovative cellular immunotherapy research and application. On the other hand, EurekaBio possesses extensive expertise in automation technology and lentiviral vector technology. Through this collaboration, the synergistic fusion of their respective strengths will accelerate the advancement of cell therapy drug research and commercialization efforts. Together, they will make significant contributions to the thriving development of the cell therapy industry in the Greater Bay Area, while also driving cost reduction and efficiency enhancement within the broader CGT landscape.
BinDeBio, a subsidiary of Shenzhen Binder Biotechnology Co., Ltd., was established in 2015. It is a biotechnology group company specializing in immune cell-based cancer treatment. Focused on leveraging the internationally leading CAR-T and TCR-T cellular immunotherapy technologies, BinDeBio is committed to the development and commercialization of immunotherapy. With a team of highly skilled professionals, BinDeBio possesses extensive expertise in advanced CAR-T and TCR-T immunotherapy technologies and holds complete intellectual property rights. The company demonstrates exceptional capabilities in developing and applying innovative cellular immunotherapies, supported by a well-experienced management and production team. BinDeBio has received strong support from the Shenzhen Municipal Government and has established extensive and in-depth cooperation with the Chinese Academy of Sciences and several authoritative hospitals nationwide.
BinDeBio has successfully developed a comprehensive immunotherapy industry chain, comprising an intelligent immune detection company and a clinical-level cell preparation company. Through partnerships with major hospitals and oncology rehabilitation institutions, BinDeBio has established an internationally recognized platform for tumor treatment and recovery. This integrated platform seamlessly manages cancer therapy and rehabilitation, aiming to enhance patients' quality of life and maximize their life expectancy.
EurekaBio is a company dedicated to the research and development of core technologies and processes in CGT. Through the integration of automation technology and biotechnology, EurekaBio has independently developed two fully closed and automated cell processing systems, CellSep® PRO and CellSep® MAX. These systems assist in upgrading cell therapy processes from manual preparation to automated and standardized production. The CellSep® PRO system has been widely adopted by numerous cell therapy companies, empowering the IND application, Phase I and Phase II clinical trials, and product development of cell therapies including CAR-T, TCR-T, CAR-NK, TIL, and stem cells.
To address the challenges in lentiviral vector production, EurekaBio has innovatively developed the EuLV® system and associated scale-up processes This system, based on stable producer cell lines, enables large-scale production of lentiviral vectors. It effectively addresses the technical bottleneck associated with scaling up lentiviral vector production, leading to significant improvements in production efficiency and consistency, and cost reduction.
.jpg)
